1,028.65
+5.44%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sakar Healthcare
Its shares trade on NSE under the ticker SAKAR.NS. It has been listed since 14 October 2016. In the fiscal year to 31 March 2026, it reported revenue of ₹2.52bn and net income of ₹304.8m. At that date it held total assets of ₹4.81bn and shareholders' equity of ₹3.24bn.
Sakar Healthcare Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2016-10-14. The firm is engaged in providing liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectables (SVP) in ampoules, vials and lyophilized injections, oral solid dosages, and research and development of these products. The Company’s products include Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin - Oral Solid and Lyophilised Injections (In Vials). The firm operates as a contract development and manufacturing organization (CDMO). The firm has approximately 321 product registrations in various countries. The manufacturing unit has been accredited by regulatory authorities of 14 countries, which includes Uganda, Kenya, Yemen, Ethiopia, Congo, Zimbabwe, Nigeria, Malawi, Philippines, Peru, Vietnam, Cote D’Ivoire.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Oct 2016
- Employees
- 297
- Website
- sakarhealthcare.com ↗
Leadership
Pay as last reported
- Mr. Sanjay ShahChairman of the Board, Managing Director, since 2004₹4.8m
- Mr. Dharmesh ThakerChief Financial Officer
- Mr. Sudhir GhuleChief Operating Officer
- Mr. Bharat SoniCompliance Officer, Company Secretary
- Mr. Aarsh ShahJoint Managing Director, Director, since 2012₹3.6m
- Mr. Sunil MaratheWhole Time Director - Technical, since 2023
- Ms. Vishalakshi ChandramouliNon-Executive Non-Independent Director
- Ms. Rita ShahNon-Executive Director, since 2004₹1.2m
- Ms. Reeya KothariIndependent Director
- Ms. Hiral PatelIndependent Director
- Ms. Megha SamdaniIndependent Director
- Mr. Jignesh ParikhAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sakar Healthcare Ltd. manufactures liquid orals and cephalosporin products in Ahmedabad, India.
- The company has 321 product registrations across 14 countries including Uganda and Kenya.
- Sakar Healthcare operates as a CDMO with manufacturing accreditation in 14 countries such as Nigeria and Vietnam.
Weaknesses
- Sakar Healthcare employs 297 full-time employees in Ahmedabad, Gujarat.
- The company's IPO was on 14 October 2016, a relatively recent listing.
- Sakar Healthcare's business focuses on pharmaceutical products like dry powder injections and oral solid dosages.
Opportunities
- Sakar Healthcare can expand its CDMO services in the Health Care sector across 14 countries including Peru and Vietnam.
- The firm's 321 product registrations in countries like Philippines and Cote D’Ivoire offer growth potential.
- Sakar Healthcare's manufacturing unit accreditation in 14 countries supports market expansion opportunities.
Threats
- Sakar Healthcare faces competition in the Health Care sector from other pharmaceutical manufacturers in India.
- The company's reliance on pharmaceutical products like liquid injectables may pose market risks.
- Regulatory changes in countries such as Yemen and Ethiopia could impact Sakar Healthcare's operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.